Published in Cancer Res on June 15, 1998
Human telomerase and its regulation. Microbiol Mol Biol Rev (2002) 3.11
Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med (2005) 2.53
Global changes in STAT target selection and transcription regulation upon interferon treatments. Genes Dev (2005) 2.01
Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol (2006) 1.82
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry (2008) 1.80
20-Hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-kappaB activity by increasing IkappaB alpha levels in human keratinocytes. PLoS One (2009) 1.65
Natural alpha interferon-producing cells respond to human immunodeficiency virus type 1 with alpha interferon production and maturation into dendritic cells. J Virol (2003) 1.64
Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am (2007) 1.63
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A (1999) 1.55
MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem (2011) 1.46
Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun (2012) 1.36
Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol (2010) 1.26
Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci U S A (2005) 1.25
Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J Virol (2000) 1.22
System-based proteomic analysis of the interferon response in human liver cells. Genome Biol (2004) 1.09
Hepatitis C and interferon induced thyroiditis. J Autoimmun (2010) 1.08
Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab (2009) 1.04
Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virol J (2005) 1.04
Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients. Clin Exp Immunol (2002) 1.03
IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. J Immunol (2008) 1.02
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood (2007) 1.02
Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J Virol (2002) 1.02
A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci U S A (1999) 1.01
The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling. J Mol Biol (2007) 0.99
Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology (2009) 0.98
Possible involvement of the double-stranded RNA-binding core protein sigmaA in the resistance of avian reovirus to interferon. J Virol (2000) 0.97
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther (2015) 0.97
Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis (2004) 0.96
Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells. Antimicrob Agents Chemother (2003) 0.95
A Grid-based solution for management and analysis of microarrays in distributed experiments. BMC Bioinformatics (2007) 0.95
Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents. J Biol Chem (2009) 0.95
Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J Cell Mol Med (2008) 0.95
AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromolecular Med (2009) 0.95
Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue. Psychol Med (2011) 0.94
Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study. Drug Des Devel Ther (2013) 0.94
Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Mol Cell Proteomics (2009) 0.94
Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res (2006) 0.90
Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Rev Mol Med (2011) 0.90
Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J Biol Chem (2011) 0.90
Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne) (2015) 0.89
Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. Br J Cancer (2005) 0.88
Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One (2011) 0.87
Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci (2010) 0.86
Hendra and nipah infection: pathology, models and potential therapies. Infect Disord Drug Targets (2011) 0.84
Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol (2009) 0.84
Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model. J Transl Med (2013) 0.84
Double-stranded RNA induces biphasic STAT1 phosphorylation by both type I interferon (IFN)-dependent and type I IFN-independent pathways. J Virol (2012) 0.83
Inhibition of type I interferon-mediated antiviral action in human glioma cells by the IKK inhibitors BMS-345541 and TPCA-1. J Interferon Cytokine Res (2012) 0.82
Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism. Br J Cancer (2000) 0.82
In vitro resistance to interferon of hepatitis B virus with precore mutation. World J Gastroenterol (2005) 0.81
Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol (2005) 0.81
Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine Growth Factor Rev (2007) 0.80
Bioelectric applications for treatment of melanoma. Cancers (Basel) (2010) 0.80
The role of consensus interferon in the current treatment of chronic hepatitis C viral infection. Gastroenterol Hepatol (N Y) (2008) 0.79
Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma. Int J Mol Sci (2014) 0.79
Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function. Am J Pathol (2002) 0.79
An interferon response gene signature is associated with the therapeutic response of hepatitis C patients. PLoS One (2014) 0.79
Regulation of cysteinyl leukotriene receptor 2 expression--a potential anti-tumor mechanism. PLoS One (2011) 0.79
Interleukin-2 from Adaptive T Cells Enhances Natural Killer Cell Activity against Human Cytomegalovirus-Infected Macrophages. J Virol (2015) 0.79
Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells. J Zhejiang Univ Sci B (2012) 0.78
The induction of type I interferon production in hepatitis C-infected patients. J Interferon Cytokine Res (2009) 0.78
In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma. Br J Cancer (2004) 0.77
The Type I IFN-Induced miRNA, miR-21. Pharmaceuticals (Basel) (2015) 0.77
Activated CD4+ T cells enhance radiation effect through the cooperation of interferon-gamma and TNF-alpha. BMC Cancer (2010) 0.76
Recombinant human interferon alpha 2b prevents and reverses experimental pulmonary hypertension. PLoS One (2014) 0.76
B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha. Clin Dev Immunol (2012) 0.76
Bortezomib sensitizes human glioblastoma cells to induction of apoptosis by type I interferons through NOXA expression and Mcl-1 cleavage. Biochem Biophys Res Commun (2016) 0.75
Passive broad-spectrum influenza immunoprophylaxis. Influenza Res Treat (2014) 0.75
Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy. Int J Appl Basic Med Res (2016) 0.75
IFNα gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment. EMBO Mol Med (2016) 0.75
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A (1998) 13.39
Interleukin-1. Rev Infect Dis (1984) 11.24
Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol (1986) 10.92
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A (1984) 8.84
Interferons and their actions. Annu Rev Biochem (1987) 8.36
Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell (1990) 7.12
Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J (1995) 6.94
Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol (2001) 6.19
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 5.91
Human leukocyte interferon produced by E. coli is biologically active. Nature (1980) 5.86
Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med (1981) 5.76
Inhibitors of ribosome functions. Annu Rev Microbiol (1971) 5.56
Natural cell-mediated immunity. Adv Cancer Res (1978) 5.53
Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol (1984) 5.51
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest (1988) 5.22
Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med (1984) 5.12
Natural killer cells: their roles in defenses against disease. Science (1981) 4.59
Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci U S A (1994) 4.53
ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res (2001) 4.47
Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science (1986) 4.25
A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci U S A (1997) 3.88
Synthesis of human fibroblast interferon by E. coli. Nucleic Acids Res (1980) 3.75
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. EMBO J (1992) 3.65
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer (1975) 3.54
Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest (1998) 3.54
Inhibition of cell-free protein synthesis by pppA2'p5'A2'p5'A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell (1978) 3.53
Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol (1977) 3.52
Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci U S A (2000) 3.51
Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med (1983) 3.49
Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology (1999) 3.44
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 3.43
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol (1986) 3.35
Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J (1997) 3.34
Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation. Cell Immunol (1981) 3.22
IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A (2001) 3.21
Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A (1977) 3.15
Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol (1984) 3.07
Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest (1986) 3.05
Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol (1981) 3.05
Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med (1974) 2.98
Convenient assay for interferons. J Virol (1981) 2.95
An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol (1985) 2.90
Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science (1988) 2.87
Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest (1990) 2.86
Mre11 complex and DNA replication: linkage to E2F and sites of DNA synthesis. Mol Cell Biol (2001) 2.85
Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med (1985) 2.84
Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest (2001) 2.84
Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science (1986) 2.83
Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A (2000) 2.83
Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest (1986) 2.82
Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol (1979) 2.80
Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). J Clin Immunol (1999) 2.79
Lymphokines. N Engl J Med (1987) 2.77
Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum (1983) 2.75
Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Nature (1995) 2.74
NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol (2000) 2.71
Molecular basis of fever in humans. Am J Med (1982) 2.69
The importance of Th2 cytokines in protective immunity to nematodes. Immunol Rev (1992) 2.69
Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. EMBO J (1998) 2.68
Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol (1986) 2.68
PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J Biol Chem (2001) 2.67
Interferon-induced binding of nuclear factors to promoter elements of the 2-5A synthetase gene. EMBO J (1988) 2.66
Collagen fibril formation. Optimal in vitro conditions and preliminary kinetic results. J Biol Chem (1978) 2.65
The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. J Biol Chem (1999) 2.64
Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med (1979) 2.64
Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999) 2.63
A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1977) 2.60
Heterogeneity of natural killer cells. Annu Rev Immunol (1984) 2.59
Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci U S A (1999) 2.57
Functional expression and RNA binding analysis of the interferon-induced, double-stranded RNA-activated, 68,000-Mr protein kinase in a cell-free system. Mol Cell Biol (1991) 2.55
A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J (1991) 2.52
Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem (1982) 2.49
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest (1978) 2.48
Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45
Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J Immunol (2001) 2.41
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol (1989) 2.41
IL-1 induction-capacity of defined lipopolysaccharide partial structures. J Immunol (1989) 2.41
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40
Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer (1977) 2.39
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 2.37
Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science (1991) 2.37
Cell-free translation of immunoglobulin messenger RNA from MOPC-315 plasmacytoma and MOPC-315 NR, a variant synthesizing only light chain. Proc Natl Acad Sci U S A (1975) 2.37
Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med (1974) 2.35
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol (1984) 2.34
Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med (1989) 2.33